Floatz logo

Capecitabine

PR-Positive Breast Cancer

Massachusetts General HospitalSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the PR-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Massachusetts General Hospital
Phase 2B
Vinorelbine
Massachusetts General Hospital
Phase 2B
Trastuzumab Emtansine
Massachusetts General Hospital
Phase 2CCC
Neratinib
Massachusetts General Hospital
Phase 2CCC
TAMOXIFEN
Jennifer Lee Caswell-Jin
Phase 1CC
Omnipaque
Jennifer Lee Caswell-Jin
Phase 1CC
Iopamidol
Jennifer Lee Caswell-Jin
Phase 1CC
Infigratinib
Jennifer Lee Caswell-Jin
Phase 1CC

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →